Home / Health / New Obesity Drug Aleniglipron Shows Promising Weight Loss
New Obesity Drug Aleniglipron Shows Promising Weight Loss
9 Dec
Summary
- Aleniglipron demonstrated 11.3% mean weight loss in Phase IIb study.
- Up to 15.3% weight loss observed with higher doses in exploratory trial.
- Structure Therapeutics plans Phase III meeting with FDA soon.
Structure Therapeutics has reported significant positive outcomes from its ACCESS clinical programme, evaluating the investigational oral GLP-1 receptor agonist, aleniglipron.
The core Phase IIb study revealed that participants receiving aleniglipron at a 120mg dose achieved an 11.3% placebo-adjusted mean weight loss after 36 weeks. Exploratory trials indicated even greater weight loss, up to 15.3% with a 240mg dose, while maintaining a tolerability profile consistent with the GLP-1 receptor agonist class.
Further analysis from extension studies showed persistent weight loss and enhanced tolerability when treatment initiated at a lower 2.5mg dose. No drug-induced liver injury or liver enzyme increases were reported across all studies. The company is preparing for a pivotal Phase III design meeting with the US FDA.
